# V. Gounant

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/v-gounant/

## Facts

| Field | Value |
| --- | --- |
| Citations | 6,106 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 35 |
| i10-index | 79 |
| Last Known Institution | Lyon 1 Université |
| OpenAlex ID | https://openalex.org/A5056853165 |
| ORCID iD | 0000-0002-9473-1247 |
| Works | 321 |

## Researcher papers

- [Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry](https://scholariq.org/papers/immune-checkpoint-inhibitors-for-patients-with-advanced-lung-cancer-and/)
- [Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/bevacizumab-for-newly-diagnosed-pleural-mesothelioma-in-the-mesothelioma-avastin/)
- [Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients](https://scholariq.org/papers/immune-checkpoint-inhibitors-associated-with-interstitial-lung-disease-in-cancer/)
- [A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial](https://scholariq.org/papers/a-randomized-non-comparative-phase-ii-study-of-anti-programmed-cell-death-ligand/)
- [Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer](https://scholariq.org/papers/association-of-tp53-mutations-with-response-and-longer-survival-under-immune/)
- [Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma](https://scholariq.org/papers/efficacy-of-immune-checkpoint-inhibitors-in-lung-sarcomatoid-carcinoma/)
- [Six-month prognosis of patients with lung cancer admitted to the intensive care unit](https://scholariq.org/papers/six-month-prognosis-of-patients-with-lung-cancer-admitted-to-the-intensive-care/)
- [From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)](https://scholariq.org/papers/from-randomized-trials-to-the-clinic-is-it-time-to-implement-individual-lung/)
- [Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study](https://scholariq.org/papers/resistance-mechanisms-to-osimertinib-in-egfr-mutated-advanced-non-small-cell/)
- [Clinicopathologic Features and Response to Therapy of<i>NRG1</i>Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry](https://scholariq.org/papers/clinicopathologic-features-and-response-to-therapy-of-i-nrg1-i-fusion-driven/)
- [Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study](https://scholariq.org/papers/histomolecular-resistance-mechanisms-to-first-line-osimertinib-in-egfr-mutated/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Pleural and Pulmonary Diseases](https://scholariq.org/topics/pleural-and-pulmonary-diseases/)

## Researcher university

- [Lyon 1 Université](https://scholariq.org/institutions/lyon-1-universite/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.